BRIEF-Aralez Pharmaceuticals' drug BLEXTEN receives Health Canada approval

Mon Apr 25, 2016 7:12am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

April 25 (Reuters) - Aralez Pharmaceuticals Inc

* Aralez pharmaceuticals says Health Canada approved BLEXTEN for treatment of symptoms of seasonal allergic rhinitis, chronic spontaneous urticaria

* BLEXTEN will be distributed in Canada by Tribute Pharmaceuticals Canada Inc., a subsidiary of company Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)